RUMOR: Whitehouse Station Bidding — Up To $4B — For Amylin?

It makes sense, but it is still far too early to verify the accuracy of these rumor pieces — see this from Barron’s — quoting Bloomberg:

. . . .Merck. . . put in first-round offers for diabetes drug maker Amylin Pharmaceuticals, according to sources close to the private negotiations.

As Bloomberg is reporting the bids were for at least $25 a share, valuing the company at more than $4 billion, based on its shares outstanding as of April 26. . . .

An interesting diabetes-space play, if accurate (given Merck’s Januvia/Janumet franchises). Do stay tuned — and have a safe Memorial Day Weekend!


There are no comments on this post.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: